Complicity theory: An explanation for the 'coxib problem'?

Journal of the Royal Society of Medicine

Volumn 99, Issue 6, 2006, Pages 273-274

  Dieppe, Paul ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ANALGESIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPLICITY; DRUG COST; DRUG INDICATION; DRUG INDUSTRY; DRUG INHIBITION; DRUG MARKETING; DRUG RESEARCH; DRUG SCREENING; EDITORIAL; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TRACT; HEALTH PRACTITIONER; HEART INFARCTION; HUMAN; INFLAMMATION; MEDICAL EDUCATION; MEDICAL LITERATURE; MEDICAL PRACTICE; PHYSICIAN; PRESCRIPTION; RISK FACTOR;

EID: 33745752267     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1258/jrsm.99.6.273     Document Type: Editorial

References (17)

1. Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 2006;99:132-40
2. Curfman G, Morrissey S, Drazen J. Expression of Concern Reaffirmed. N Engl J Med 2006;354:1193
3. Weatherall M, Aldington S, Caldwell B, Beasley R. Inconsistencies in cardiovascular data from COX-2 inhibitor trials-is it a CLASS effect? J R Soc Med 2006;99:275-6
4. Hawkey C, Langman M. Non-steroidal anti-inflammatory drugs: overall risk and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut 2003;52:600-8
5. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. JAMA 2000;284:1247-55
6. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity with rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N Engl J Med 2000;343:1520-8
7. McAdam B, Catella-Lawson F, Mardini I, Kapoor S, Lawson J, Fizgerald G. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Nat Acad Sci 1999;96:272-7
8. Dieppe P, Bartlett C, Davey P, Doyal L, Ebrahim S. Balancing benefits and harms: the example of non-steroidal anti-inflammatory drugs. BMJ 2004;329:31-4
9. Dieppe P, Ebrahim S, Martin R, Juni P. Lessons from the withdrawal of rofecoxib. BMJ 2004;329:867-8
10. Kline A. On complicity theory. Sci Eng Ethics 2006;12:257-64
11. [http://www.nofreelunch.org]
12. Watson D, Rhodes T, Cai B, Guess H. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002;162:1105-10
13. Juni P, Rutjs AW, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 2002;324:1287-8
14. Angell M. The Truth About The Drug Companies: How They Deceive Us and What To Do About It. London: Random House, 2005
15. Weber L. Profits Before People?: Ethical Standards and The Marketing and Prescription of Drugs. Indiana: Indiana University Press, 2006
16. Marteau T, Dieppe P, Foy R, Kinmonth AL, Schneiderman N. Behavioural medicine: changing our behaviour. BMJ 2006;332:437-8
17. Moynihan R, Cassels A. Selling Sickness: How The World's Biggest Pharmaceutical Companies Are Turning Us All Into Patients. California: Avalon Publishing Group, 2005